NCT06599957Recruiting
Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy
Source: ClinicalTrials.gov · Last updated 22 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
DEEPLY aims to improve sarcoma therapy by the development of an innovative nanophotonic delivery approach to be applied in the future as an integrated local therapy for patients with inoperable tumors or with oligometastases. The major aim of the project is the development of innovative nanocarriers loaded with chemotherapeutic agents, whose delivery will be improved by the use of an optic fiber (optoporation). After the synthesis, and characterization of NPs, a prototype will be produced and preclinically validated on patient-derived biological material. This wide comprehensive methodological approach will ensure the obtainment of robust data to be faster exploited toward clinical applications.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 10 Sept 2024
- Start date
- 30 Aug 2024
- Primary completion date
- 30 Aug 2026
- Lead sponsor
- Istituto Ortopedico Rizzoli
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT06599957
What you commit to
- Study type: Observational
- Planned participants: 30
- From 30 Aug 2024 to the primary completion date, 30 Aug 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients not affected by STSs or BSs will be excluded from the study, as well as patients with multiple primary tumors.
Who the study is looking for
- Patients eligible for the study will be male or female, with an age ranging from 0- to 85 years, undergoing surgery or biopsy for STSs or BSs including osteosarcomas.
- Included patients may have undergone or may be still in treatment with chemotherapy (also neo-adjuvant settings), targeted therapy, radiotherapy, or combination therapy.
- IRST will enroll only adult patients (age \> 18 years).
- Signed informed consent from all subjects enrolled in the study. IOR patients will have to sign both the specific project Informed Consent and the IOR Biobank Informed consent.
Age in the registry: 2 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istituto Ortopedico Rizzoli-OSOTT Coordinator of this site? Confirm its status | Bologna | Italy | Recruiting |
| IRCCS - Istituto Romagnolo per lo Studio Dei Tumori, Dino Amadori Coordinator of this site? Confirm its status | Meldola | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.